BI 1291583

This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated

A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy Men

A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the Blood

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body

A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY TM Study)